Woodmont Investment Counsel’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$552K Hold
5,574
0.03% 186
2026
Q1
$483K Hold
5,574
0.03% 192
2025
Q4
$473K Hold
5,574
0.03% 187
2025
Q3
$404K Hold
5,574
0.03% 198
2025
Q2
$365K Hold
5,574
0.02% 223
2025
Q1
$393K Hold
5,574
0.03% 209
2024
Q4
$366K Buy
+5,574
New +$384K 0.03% 208

Other funds holding IHE

Woodmont Investment Counsel's IHE Position: Q2 2026 in Review

Woodmont Investment Counsel held its iShares US Pharmaceuticals ETF (IHE) position steady in Q2 2026 at 5,574 shares worth $552K. The position accounts for 0.03% of the portfolio, ranked #186.

Woodmont Investment Counsel first reported a position in IHE in Q4 2024 and has held it in 7 quarters since. 91 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

  • Woodmont Investment Counsel held 5,574 shares of iShares US Pharmaceuticals ETF worth $552K as of Q2 2026.
  • Woodmont Investment Counsel left its iShares US Pharmaceuticals ETF share count unchanged in Q2 2026.
  • iShares US Pharmaceuticals ETF made up 0.03% of Woodmont Investment Counsel's portfolio in Q2 2026, its #186 holding.
  • Woodmont Investment Counsel first reported a position in iShares US Pharmaceuticals ETF in Q4 2024 and has held it in 7 quarters since.
  • 91 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Woodmont Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.